Ingredient Beauty BenefitsOther · Hexylresorcinol
Hexylresorcinol: the control was niacinamide alone — the design this site wanted, with no participant count
The trial on this ingredient has the design this site keeps wishing for — the control was not a vehicle but niacinamide alone. Randomised, double-blind, split-face, over 12 weeks, the combination beat niacinamide alone significantly on pigment spots (L*), fine lines and skin firmness. But all the authors are at the manufacturer's research arm, and the abstract gives no participant count.
Last checked Oct 2, 2026
Start here
- What it is
A synthetic ingredient of the resorcinol family. It has been reported to inhibit tyrosinase.
- What it is used for
For uneven pigmentation, most often in products that also contain niacinamide.
- How it is said to work
It is said to slow the enzyme that makes pigment.
There are no numbers and no citations in this box. What has been established, and how far, is below.
At a glance
- In pregnancy
- Not established
- Irritation
- Low
- Daytime use
- ✓ Fine
- How well established
- Early research
- Concentration studied
- Not disclosed
- Length of the studies
- 12 weeks
Not a measurement — reported irritation grouped into five steps. It varies between people.
“Concentration studied” and “Length of the studies” are taken straight from the research on this page. They are not a recommended dose, and the figure for each finding is written out in the text.
This is not how large the effect is but how well confirmed it is. It shows the highest grade among the findings on this page.
Hexylresorcinol is a synthetic ingredient of the resorcinol family. It has been reported to inhibit the enzyme that makes pigment (tyrosinase).
First, the names have to be separated. This site has two similar ones.
- this page — 4-hexylresorcinol
- 4-n-butylresorcinol
They are different molecules. The attached chain differs in length, and the trials are separate. Do not read the two as one on an ingredient list.
And this page has something this site has long wanted — a design.
On the pycnogenol, N-acetyl glucosamine and cryotherapy pages this site wrote the same regret over and over — it was added on top of something that already works, and because the control was 'nothing', the added part's share cannot be known.
This trial did that design. The control was niacinamide alone. That is, both sides got niacinamide, and the only thing that differed was the hexylresorcinol. The same shape as the 'laser + petrolatum' control on the laser-assisted drug delivery page.
And yet that good question is held up by very little. All the authors are at Unilever R&D, and the abstract gives no participant count. Both are set out below.
On pigmentation, the items with thicker evidence here are tranexamic acid, thiamidol and azelaic acid.
Contents
What is established
The same ingredient at a different strength, in a different formula, is a different product. These are the conditions the studies used.
It beat niacinamide alone — but the abstract gives no participant count
A 2022 trial in Int J Cosmet Sci. The paper carries cell work and a human trial together, and this site counts only the human side as a badge.
The human trial's design. In Chinese subjects, randomised, double-blind, split-face, over 12 weeks. Skin tone, hyperpigmentation, fine lines and wrinkles, hydration and skin firmness were measured.
And the control matters — niacinamide alone.
The results.
- the combination was significantly better than niacinamide alone on hyperpigmentation spots — measured by L*, a colour value
- also significantly better on the visual appearance of fine lines and wrinkles in the crow's feet and perioral area
- also significantly better on skin firmness
- no product-related adverse events
The paper concludes that the combination delivered superior skin tone and anti-ageing benefits significantly better than niacinamide alone, and that it may provide an additional option beyond hydroquinone and retinoids.
Now how to read it.
First, we start by praising the design. The control was niacinamide alone. The very question this site keeps regretting on other pages — the share of what was added — is the question this trial asked. And split-face means it compared within one person. It is double-blind.
Second, and yet the abstract gives no participant count. How many took part is absent. We do not invent it. That is why the participant field on the badge is empty. And without the number, the weight of 'significant' cannot be read. A split-face design is sensitive, but 20 people and 200 are not the same.
Third, the funding. All thirteen authors are at Unilever R&D (Bangalore, Shanghai and Trumbull). This site marks that as industry funding. It does not mean the result is false. But this site's 'strong evidence' is not attached when everything is industry-funded, and this entry could not reach that place anyway, being one trial.
Fourth, we do not count cell work as a result in people. Half the paper is cultured melanocytes and a 3D skin model. That tyrosinase inhibition was potent is also from that side. This site does not put it on the badge.
Fifth, the concentration is not in the abstract. What percentage was used is not stated. This site does not estimate concentrations it has not read. The concentration field on the badge is empty.
Sixth, read the significance on fine lines and firmness with care. Several endpoints all coming out significant in one trial can be a good sign, or the result of running many comparisons. This site wrote that problem out in detail on the topical melatonin page. And the abstract says nothing about correction.
Seventh, 12 weeks, one trial.
So it sits at 'early evidence'. The question is good and the design is good, but there is no participant count, no concentration, and every author is at the manufacturer. That combination is rare on this site — usually it is the question that blurs first, whereas here the question is sharp and what holds it up is thin.
- Randomised controlled trial in people · sample size not reported · 12 weeks · Compared with another active ingredient · Funding manufacturer-funded · Endpoint instrument measurement PMID 34958693
The other trial mixed four ingredients together
A 2016 trial in J Drugs Dermatol. First, why this entry has no badge.
We could not verify this paper's detailed figures from its abstract. So we carry it as a source only and leave the grade down. This site handles a paper the same way on the fractional laser page.
But there is one thing the title alone lets us write. Here is what was in the product that trial looked at.
- retinol 0.5%
- niacinamide
- hexylresorcinol
- resveratrol
Four things. And this site has separate pages for three of them — retinol, niacinamide and resveratrol.
Open those three pages and you can see why this entry gets no badge. Retinol at 0.5% is a concentration that carries evidence of its own on this site. That a product containing four things improved does not say which of them moved.
That is the difference from the entry above. The 2022 trial set its control as niacinamide alone and asked for the added part's share. This 2016 trial put four things in at once. Two trials on the same ingredient, opposite in the quality of their design.
So it sits at 'not established'. What this entry does is record that the trial exists, and what it mixed.
How to use it
- The concentration in the 2022 trial is not in the abstract. This site does not estimate concentrations it has not read. If a product does not state one, treat it as not stated.
- Products containing it with niacinamide are common, and that combination is what the trial looked at. What matters is that the control was niacinamide alone — the combination beating that alone is the trial's result.
- It is a different ingredient from 4-n-butylresorcinol. Do not read the two as one on a label.
- Judge over 12 weeks. That is the period the trial covered.
- In pigmentation, sunscreen is not background but a condition. Use it alongside.
- For thicker evidence on pigmentation, tranexamic acid, thiamidol and azelaic acid come first here.
Cautions
- Irritation and contact dermatitis have been reported for the resorcinol family. Test a small area first.
- The 2022 trial reported no product-related adverse events. But the abstract gives no participant count, and it is 12 weeks.
- We found no data on use in pregnancy or breastfeeding.
- Uneven pigmentation has several causes. Melasma, post-inflammatory pigmentation and sun-driven spots differ. Start from the pigmentation page.
With a new ingredient, apply a small amount somewhere inconspicuous, such as the inner arm, for two days first. Stop if it reddens or stings.
Related skin concerns
What this article relies on
- PubMed — 미국 국립의학도서관 문헌 데이터베이스National Library of Medicine · Checked on 2026-09-16